Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “sell” rating restated by analysts at The Goldman Sachs Group in a research report issued to clients and investors on Thursday, MarketBeat reports. They presently have a $56.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential downside of 13.39% from the company’s current price.

HALO has been the subject of a number of other research reports. JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Friday, November 28th. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $75.10.

Halozyme Therapeutics Trading Down 2.8%

Shares of NASDAQ:HALO opened at $64.66 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics has a 12-month low of $46.26 and a 12-month high of $79.50. The business has a 50 day moving average of $68.61 and a two-hundred day moving average of $64.20. The company has a market capitalization of $7.60 billion, a PE ratio of 13.61, a PEG ratio of 0.37 and a beta of 0.95.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. During the same period in the previous year, the firm earned $1.27 EPS. The business’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $48,844,913.48. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 829 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the sale, the director owned 42,123 shares of the company’s stock, valued at approximately $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 103,625 shares of company stock worth $7,446,727. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $25,000. Larson Financial Group LLC grew its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Richardson Financial Services Inc. increased its stake in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Wealth Preservation Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at approximately $32,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $32,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.